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Abstract: Worldwide, there is growing concern about the burden of pneumonia. Severe community-acquired
pneumonia (CAP) is frequently complicated by pulmonary and extra-pulmonary complications,
including sepsis, septic shock, acute respiratory distress syndrome, and acute cardiac events, resulting
in significantly increased intensive care admission rates and mortality rates. Streptococcus pneumoniae
(Pneumococcus) remains the most common causative pathogen in CAP. However, several bacteria
and respiratory viruses are responsible, and approximately 6% of cases are due to the so-called PES
(Pseudomonas aeruginosa, extended-spectrum β-lactamase Enterobacteriaceae, and methicillin-resistant
Staphylococcus aureus) pathogens. Of these, P. aeruginosa and methicillin-resistant Staphylococcus aureus
are the most frequently reported and require different antibiotic therapy to that for typical CAP.
It is therefore important to recognize the risk factors for these pathogens to improve the outcomes in
patients with CAP.
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1. Severe Community-Acquired Pneumonia: What Is the Current Definition?
Currently, there is no consensus for the definition of severe community-acquired pneumonia
(CAP) largely because it includes such a heterogeneous patient group. The most widely accepted
definition is based on the 2007 Infectious Diseases Society of America/American Thoracic Society
consensus (ATS/IDSA) guidelines for the management of CAP in adults [1]. According to the
ATS/IDSA guidelines, severe CAP is defined by the presence of two major criteria: the need for
invasive mechanical ventilation (IMV) due to severe acute respiratory failure and/or the presence of
septic shock (Table 1). Several minor criteria requiring high intensity monitoring and treatment have
also been proposed [1].
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Blood urea nitrogen level ≥20 mg/dL (7.14 mmol/L)
Confusion/disorientation
Hypotension requiring aggressive fluid resuscitation
Hypothermia (core temperature <96.8◦F (36 ◦C))
Leukopenia (white blood cell count <4000 cells/mm3 (4.00 × 109/L))
Multilobar infiltrates
PaO2/FiO2 ratio ≤250
Respiratory rate ≥30 breaths/minute
Thrombocytopenia (platelets <100 × 103 cells/mm3 (100 × 109/L))
ATS/IDSA, American Thoracic Society/Infectious Disease Society of America; FiO2, fraction of inspired oxygen;
PaO2, partial arterial oxygen pressure.
2. Admission to Intensive Care Units: What Is the Real Impact?
During recent decades, the numbers of patients with pneumonia requiring management
in intensive care has grown globally. The aging population [2] and the increasing number of
immunocompromized patients [3–5] (e.g., due to solid organ and hematopoietic stem cell
transplantation, human immunodeficiency virus, or biological or immunosuppressive therapies)
probably explains much of this change.
The percentage of admissions to intensive care units (ICUs) that are attributable to elderly patients
ranges from 9% to 19% in Europe [6–11] and from 20% to 30% in America [12]. A recent French study of
ICU admission trends among elderly patients (≥75 years) between 2006 and 2015 indicated that 3% of
all hospitalizations (3,856,785 cases) were for an acute respiratory infection (ARI) (98,381 cases) and
that 15% of these required ICU admission (15,267 cases). The authors noted that the annual number of
ICU hospitalizations increased steadily from 740 to 2034 during the study, with a 2.7-fold increase in
ICU admissions for respiratory infection (p = 0.002). There was an overall increase in the number of
ICU admissions for all age groups but with the greatest increases in ICU resources seen for patients
aged 85–89 years (3.3 fold) and ≥90 years (5.8 fold). Interestingly, the increased ICU admission rate
was not associated with significant changes in the ICU mortality rate for patients with ARI, with
rates of 19.7% ± 3.0%, 24.0% ± 3.6%, and 25.0% ± 4.0% for those aged 75–79, 80–84, and 85–89 years,
respectively. Indeed, there was a significant drop in ICU mortality from 40.9% in 2006 to 22.3% in 2015
(p = 0.03) for patients aged ≥90 years [13]. Finally, they reported that hospitalizations for CAP and
acute exacerbations of chronic obstructive pulmonary disease increased significantly for all age groups
during the study period.
3. Outcomes of Patients with Severe Cap: What Are the Main Determinants?
Despite improvements in management, severe CAP is associated with significant mortality.
It is known that patients with respiratory failure and IMV, sepsis, septic shock, and decompensated
comorbidities are at greater risk of death [14–18]. In the study by Jain et al. [19] in which 2320 cases of
pneumonia were analyzed, approximately 21% of patients with CAP required ICU admission and 6%
required IMV [19]. More recently, a Spanish study [14] of 154 severe CAP cases found a higher 30-day
mortality rate (33%) in patients receiving IMV compared with non-intubated patients (18%). Patients
receiving IMV did not present higher severity scores at hospital admission according to APACHE-II,
PSI, or CURB-65 scores, but the use of IMV independently predicted 30-day mortality. The authors
concluded that, based on these results, the PSI, CURB-65, and APACHE-II scores were less suitable
than IMV for reliably identifying patients with severe CAP at higher risk of mortality. IMV, septic
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shock, worsening hypoxemia, and increased serum potassium were independently associated with
increased mortality.
Interestingly, a recently published systemic review and meta-analysis [20] that included nine
studies on the use of noninvasive ventilation (NIV) in acute hypoxemic respiratory failure showed a
protective effect for intubation and mortality with the use of NIV in patients with acute pulmonary
edema, CAP, or immunosuppression (Figure 1).
Figure 1. The outcomes in patients with severe community-acquired pneumonia (SCAP) with
non-invasive ventilation (NIV) and invasive mechanical ventilation (IMV). Intensive care unit (ICU).
X–axis showed the percentage and y-axis showed study population. Adapted from Reference [21].
Cillóniz et al. [15] investigated acute respiratory distress syndrome (ARDS) in mechanically
ventilated patients with severe CAP. Of the 5334 participants, 930 (17%) were admitted to the ICU,
462 (52%) were not ventilated, 137 (15%) received NIV, and 295 (33%) received IMV; 125 cases (29%)
met the Berlin ARDS criteria [22]. ARDS affected 2% of all patients hospitalized with CAP and 13% of
patients admitted to the ICU. According to the severity of ARDS, the 30-day mortality rates were 32%,
33%, and 60% for patients with mild, moderate, and severe ARDS, respectively.
Sepsis is another important complication of severe CAP [17]. The global incidence of
hospital-treated sepsis has been estimated at 31.5 million for sepsis and 19.5 million for severe sepsis,
with a potential 5.3 million annual deaths in high-income countries [23]. Sepsis is associated with
prolonged ICU stays and high mortality rates (20%–30%), with those rates increasing when shock is
present to approximately 45% [21].
In 2016, a Spanish study investigated the predictors of severe sepsis among 4070 hospitalized
patients with CAP. Of these, 37% presented with severe sepsis (1529 patients), of which 67% were
≥65 years and 63% had PSI risk class IV–V. The 30-day mortality of septic patients (7%) was significantly
higher than that in non-septic patients (3%; p 0.001). Predictors of severe sepsis were older age, alcohol
abuse, renal disease, and chronic obstructive pulmonary disease, whereas prior antibiotic treatment
was a protective factor [17].
Georges et al. [24] investigated the prognosis of patients admitted to the ICU with CAP after the
implementation of new care strategies, including sepsis bundles derived from the Surviving Sepsis
Campaign [25], an initial empirical antimicrobial regimen with a third-generation cephalosporin
and levofloxacin, and the use of NIV following extubation. Comparing the pre-implementation
period (1995–2000) with the implementation period (2005–2010), mortality decreased from 43.6% to
30.9% (p < 0.02). Consistent with these results, Gattarello et al. [26], in a matched case-control study
(80 cases and 80 controls) comparing 2000–2002 and 2008–2013, there was a 15% decrease in mortality
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among patients with pneumococcal pneumonia admitted to ICU. Early antibiotic administration and
combination antibiotic therapy were both independently associated with better outcomes.
4. Pathogens Beyond the Core Microorganisms of Cap: Should We Be Worried About Them?
The most frequent pathogens outside the core microorganisms of CAP are methicillin-resistant
Staphylococcus aureus (MRSA), Pseudomonas aeruginosa, Acinebacter baumannii, and various
Enterobacteriaceae [27,28]. Since antibiotic therapy for these pathogens is different from the usual
empirical therapy for CAP, it is important to recognize their main risk factors to ensure early diagnosis
and appropriate treatment.
In 2012, an international expert proposal for interim standard definitions for acquired resistance
was published to allow data comparison and to improve comprehension of the real problem of
antimicrobial resistance globally. Magiorakos et al. proposed the following definition: multidrug
resistance (MDR, or resistance to at least one agent in≥3 antibiotic groups), extensively drug resistance
(XDR, or resistance to at least one agent in all but ≤2 antibiotic groups), and pan drug resistance
(PDR, or resistance to all antibiotic groups) [29] (Table 2). In the same year, Aliberti et al. [30] analyzed
935 patients. Among them, 473 (51%) had at least 1 risk factor for MDR pathogen on admission.
The authors proposed a score that included the following variables: chronic renal failure (5 points),
prior hospitalization (4 points), nursing home residence (3 points), and other variables (0.5 points each
for cerebrovascular disease, diabetes, chronic obstructive pulmonary disease, immunosuppression,
home wound care, prior antimicrobial therapy, and home infusion therapy). The prevalence of resistant
pathogens was 38% in patients with a score of ≥3 points, compared with 8% in patients with a score of
≤0.5. The overall prevalence of PES pathogens in this study was lower than in others. The thresholds
0–0.5 points and 3–12.5 points were associated with low and high risks of MDR, respectively.
Table 2. Definitions of the various categories of drug resistance. Adapted from Reference [29].
Category Definition
Multidrug resistance (MDR) Non-susceptibility to at least one agent in three or moreantimicrobial categories
Extensively drug resistance (XDR) Non-susceptibility to at least one agent in all but two orfewer antimicrobial categories
Pan drug resistance (PDR) Non-susceptibility to all agents in all antimicrobial categories
In 2013 a study about MDR pathogens in two independent European cohorts of hospitalized
patients with CAP was published. MDR pathogens were identified in 3.3% of patients in the Spanish
cohort and in 7.6% of patients in the Italian cohort, with MRSA being the most common. In both
cohorts, there was a significantly higher prevalence of MDR bacteria among patients in the ICU
compared with patients treated on the ward [27].
In 2015, Prina et al. [31] proposed the PES score, based on the three most frequent MDR
pathogens in CAP (e.g., P. aeruginosa, extended-spectrum β-lactamase-positive Enterobacteriaceae, and
methicillin-resistant S. aureus). The following elements were included: 1 point each for age 40–65 years
and male sex; 2 points each for age >65 years, previous antibiotic use, chronic respiratory disorder,
and impaired consciousness; 3 points for chronic renal failure; and minus 1 point if fever was present
initially. The thresholds ≤1 point, 2–4 points, and ≥ 5 points indicated low, medium, and high risks of
MDR, respectively (Table 3).
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Table 3. PES score. Adapted from Reference [29].
Score to PES Pathogen Points
Age > 65 1 point
Male 2 point
Previous antibiotic use 2 point
Chronic respiratory disorder 2 point
Chronic renal disease 2 point
At Emergency
Consciousness impairment or aspiration evidence 2 point
Fever or shivers −1 point
Low risk MDR score: ≤1; Medium risk MDR score: 2-4; High risk MDR score: ≥5. PES (Pseudomonas aeruginosa,
Enterobacteriaceae extended spectrum β-lactamase-positive, and methicillin-resistant Staphylococcus aureus).
Also in 2015, a score was developed by Falcone et al. [28] (the ARUC score) based on the following:
1 point for healthcare-associated pneumonia (HCAP) criteria (defined by the presence of at least one of
hospitalization in the previous 3 months, dialysis, intravenous chemotherapy in the past 30 days,
admission to an acute care hospital for at least 2 days, surgery in the past 90 days, or resided in a
nursing home or long-term care facility); 0.5 points for bilateral pulmonary infiltrations and pleural
effusion; and 1.5 points for a PaO2/FiO2 <300. Patients were then stratified as low (<0.5 points)
or high (≥3 points) risk for MDR pathogens. The authors analyzed 300 patients with an etiologic
diagnosis of CAP or HCAP, of which 99 (11%) presented MDR pathogens; only 12% of these required
an ICU admission.
In 2016, Webb et al. [32] proposed the DRIP (drug resistance in pneumonia) score based on major
and minor risk factors. Major risk factors (2 points) included prior antibiotics, residence in a long-term
care facility, tube feeding, and prior infection with a drug-resistant pathogen (1 year) and minor risk
factors (1 point) included hospitalization within the previous 60 days, chronic pulmonary disease, poor
functional status, gastric acid suppression, wound care, and MRSA colonization (1 year). A threshold of
≥4 points identified patients at high risk of pneumonia due to a drug-resistant pathogen.
In 2017, Ishida et al. [33] evaluated the risk factors for antimicrobial-resistant pathogens in
immunocompetent patients with pneumonia and validated the role of PES pathogens in this
subgroup of patients. Among the 1559 patients with CAP, an etiological diagnosis was reached
in 45% of patients and PES pathogens were identified in 7%. Patients with PES pathogens showed
a trend toward initial treatment failure, readmission within 30 days, and prolonged hospital stays.
Risk factors associated with infection by PES pathogens were female sex, admission within 90 days,
poor performance status, and enteric feeding. The authors concluded that the concept of PES pathogens
provided an appropriate description of drug-resistant pathogens associated with pneumonia in
immunocompetent patients.
Recently, the European Antimicrobial Resistance Surveillance Network (EARS-Net) published its
data regarding the burden of infections caused by antibiotic-resistant bacteria in countries of the EU and
European Economic Area in 2015 [34]. The EARS-Net estimated that there were 671,689 infections with
antibiotic-resistant bacteria, of which 64% (426,277) were health care associated. These infections
accounted for an estimated 33,110 attributable deaths and 874,541 disability-adjusted life-years.
Infants (aged <1 year) and the elderly (≥65 years) had higher burdens, as did Italy and Greece.
Moreover 80% of the total disability-adjusted life-years per 100,000 were caused by infection with
four pathogens: third-generation cephalosporin-resistant Escherichia coli, MRSA, third-generation
cephalosporin-resistant Klebsiella pneumoniae, and carbapenem-resistant Pseudomonas aeruginosa.
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Risk Scores for Specific Pathogens (MRSA and P. aeruginosa)
In 2013, Shorr et al. [35] analyzed 5975 patients admitted with bacterial pneumonia. MRSA was
identified in 14% of patients. The authors proposed a new score that included eight variables: recent
hospitalization or ICU admission (2 points), age < 30 or > 79 years (1 point), prior IV antibiotic
exposure (1 point), dementia (1 point), cerebrovascular disease (1 point), female with diabetes (1 point),
or recent exposure to a nursing home/long term acute care facility/skilled nursing facility (1 point).
The prevalence of MRSA was < 10% in low risk patients (0–1 points), approximately 22% in medium
risk patients (2 to 5 points), and >30% in high risk patients (6 or more points).
In 2018, Restrepo et al. [36] published data of a multinational point prevalence study enrolling
3193 patients in 54 countries with confirmed diagnoses of CAP and who underwent microbiological
testing at admission. The authors reported that the prevalence of P. aeruginosa was 4.2% and
the prevalence of antibiotic-resistant P. aeruginosa was 2.0%. The authors identified the following
risk factors for P. aeruginosa infection: prior Pseudomonas infection, tracheostomy, bronchiectasis,
invasive respiratory and/or vasopressor support, and severe COPD. Conversely, risk factors for
antibiotic-resistant P. aeruginosa infection were past medical history of a pseudomonas infection or
tracheostomy. According to the recommendations provided by the authors, in the absence of specific
risk factors, an empiric antibiotic therapy with a β-lactam plus a respiratory fluoroquinolone or a
macrolide is effective against most pathogens responsible for CAP. Empiric antipseudomonal should
be limited to patients with a past medical history of pseudomonas infection and/or chronic lung
diseases, independently of disease severity.
In conclusion, the continuous increase of drug resistance among virulent pathogens represents a
major challenge for clinicians and health care providers. Of course, the identification of risk factors
is a key element for the management of pathogens beyond those typical in CAP. We believe that the
concept of PES pathogens provides an accurate description of drug resistance in immunocompetent
patients with CAP.
5. Empiric Antibiotic Therapy in Severe CAP Caused by PES Pathogens: Is There Something New?
A recent study by Marayuma et al. [37] proposed an antibiotic strategy for pneumonia based on
the risk factors for PES pathogens, independent of the site of pneumonia acquisition. Risk factors
for PES pathogens were antibiotic therapy in the past 180 days, poor functional status (Barthel
Index <50 or performance status ≥3), hospitalization for >2 days in the past 90 days, occurrence of
pneumonia ≥5 days after admission to an acute hospital, requirement for hemodialysis, and
immunosuppression. The authors prospectively applied the therapeutic algorithm to a multicenter
cohort of 1089 patients, of whom 656 had CAP, 238 had HCAP, 140 had hospital-acquired pneumonia,
and 55 had ventilator-associated pneumonia. Patients with 0–1 risk factors for PES pathogens were
treated with standard therapy (a β-lactam plus a macrolide), whereas patients with ≥2 risk factors for
PES pathogens were treated with a appropriate therapy for hospital-acquired pneumonia (a two- or
three-drug regimen combining an antipseudomonal β-lactam with a quinolone or aminoglycoside
plus optional linezolid or vancomycin). Approximately 83% of patients were treated according to
the proposed algorithm, and 4% received inappropriate therapy. The authors concluded that using
an algorithm based on the risk factors for PES pathogens and disease severity rather than the site of
pneumonia acquisition, simplified treatment, improved the accuracy of empiric therapy, and reduced
mortality, avoiding the overuse of broad-spectrum antibiotics in some patients. Although this algorithm
may be promising, it has only been validated in Japan. It will, therefore, be necessary to validate the
algorithm in other countries, health care systems, and clinical settings.
Currently, the empiric antibiotic therapy for severe CAP remains based on international
guidelines that recommend using a macrolide or a respiratory fluoroquinolone in combination
with a β-lactam [1,38]. The coverage for PES pathogens should only be given if risk factors are
present. Unfortunately, the superiority of a β-lactam plus a macrolide compared to a β-lactam plus a
fluoroquinolone in the treatment of severe CAP remain unconfirmed. A recent meta-analysis [39] of
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patients with severe CAP showed that patients receiving a β-lactam plus a macrolide were discharged
from the hospital about 3 days earlier than patients treated with a β-lactam and fluoroquinolone.
The overall mortality also differed significantly between the groups, with rates of 19% for β-lactam
plus macrolide therapy and 27% for β-lactam plus fluoroquinolone therapy. However, the length of
ICU stay did not differ between the groups. More recently, a Spanish study [40] investigated the effect
on mortality of a combined β-Lactam/macrolide therapy for CAP according to the etiology and the
inflammatory status (measured by the levels of C-reactive protein). The study included 1,715 CAP
patients with known etiology; the authors found that the combination of a β-lactam with a macrolide
was associated with a lower mortality in patients with pneumococcal CAP and in patients with high
systemic inflammatory response. However, two randomized controlled trials (RCTs) showed that the
combination therapy with a β-lactam and a macrolide did not significantly reduce the mortality of
non-ICU CAP patients [41,42].
We recommend following the current international guidelines for empiric therapy in cases of
severe CAP [1] and to use the PES score [31] to identify patients at risk for PES pathogens. The use of
empiric antibiotics that cover PES pathogens should be used in patients with a PES score ≥ 5 points)
(Figure 2).
Figure 2. The management of severe community-acquired pneumonia.
6. Are There Any New Antibiotics for PES Pathogens in Severe CAP?
The research and development of new antibiotics is scientifically and economically challenging,
yet it remains an essential goal given current global needs and the spread of antimicrobial resistance.
In the European Union alone, it has been calculated that approximately 25,000 deaths are caused by
antibiotic-resistant microorganisms each year, with the global burden estimated to be 700,000 deaths
per year [43]. The production of new antibiotics has declined in recent decades, however, and between
2010 and 2018, only eight new antibiotics were registered.
Ceftobiprole is a broad-spectrum cephalosporin that has activity against many pathogens
that cause pneumonia, including gram-positive pathogens, such as penicillin-resistant Streptococcus
pneumoniae (PRSP), MRSA, and various gram-negative pathogens (including Pseudomonas species).
Ceftobiprole blocks the transpeptidase activity of the penicillin binding proteins in gram-positive and
gram-negative pathogens. This causes the synthesis of peptidoglycan to decrease and the bacterium to
die by osmosis or by autolysis. The bactericidal activity of ceftobiprole is also time dependent [44].
Results from randomized, double-blind, phase III clinical trials have demonstrated that
ceftobiprole monotherapy is noninferior to ceftriaxone both as monotherapy and in combination
with linezolid when treating severe CAP [45].
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In 2008, the US Food and Drug Administration (FDA) declined to approve ceftobiprole. However,
in 2015, it was designed as an infectious disease product for the treatment of pulmonary and
skin infectious by the FDA [46]. In contrast, in 2013, ceftobiprole was approved by the European
Medicine Agency (EMA) for the treatment of CAP and hospital-acquired pneumonia, excluding
ventilator-associated pneumonia, at a recommended intravenous dose of 500 mg every 8–12 h in
adults [47].
Ceftaroline is a fifth-generation extended-spectrum cephalosporin that binds to penicillin binding
proteins and prevents bacterial cell wall synthesis. Its antimicrobial activity is directed against
gram-positive organisms, including S. pneumoniae, Streptococcus pyogenes, S. aureus (including MRSA,
vancomycin-resistant S. aureus, and hetero-resistant vancomycin intermediate S. aureus), as well as
many common gram-negative organisms, such as Haemophilus influenzae and Moraxella catarrhalis.
Phase III clinical trials (FOCUS 1 and 2) have found that ceftaroline is noninferior to ceftriaxone for
the treatment of CAP, with cure rates exceeding 82% [48,49]. Ceftaroline is usually well-tolerated,
and in clinical trials, only 3% of subjects discontinued therapy due to adverse effects. The most
common adverse effects were rash, diarrhea, headache, hypokalemia, insomnia, and phlebitis.
The recommended adult dosage is 600 mg/12 h intravenously over 1 h for 5–7 days.
Cedftaroline was approved in 2010 for the treatment of acute bacterial skin, skin structure
infections (ABSSSIs), and community-acquired bacterial pneumonia by the FDA [50]. In 2012,
it was approved by the EMA for the treatment of complicated skin and soft tissue infections and
community-acquired pneumonia [51].
Omadacycline is a semi-synthetic aminomethylcycline derived from minocycline. It has shown
a broad spectrum of antimicrobial activity against aerobic and anaerobic gram-positive bacteria
(S. pneumoniae, S. aureus, MRSA), gram-negative bacteria (Haemophilus influenzae, Klebsiella pneumoniae),
and atypical bacteria (Chlamydophila pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae).
Moreover, it has demonstrated activity against MDR bacteria. Omadacycline binds to the 30S ribosomal
subunit and blocks bacteria protein synthesis in bacteria [52]
In a phase III clinical trial (OPTIC study) [53], omadacycline was noninferior to moxifloxacin
for the treatment of bacterial CAP. Patients were randomized to IV omadacycline 100 mg every 12 h
for two doses followed by 100 mg/day or moxifloxacin 400 mg/day for 3 days, both intravenously,
with the option to switch to oral therapy or continue for a total of 7–14 days. In the intention-to-treat
population, omadacycline performed similarly to moxifloxacin at the early clinical response evaluation
(81.1% and 82.7%, respectively). At the posttreatment evaluation, the efficacies of omadacycline versus
moxifloxacin were similar in both the intention-to-treat (87.6% vs. 85.1%) and the clinically evaluable
populations (92.9% and 90.4%, respectively). The recommended dosages for omadacycline in bacterial
CAP are as follows:
• Loading dose: 200 mg by intravenous infusion over 60 min on day 1 or 100 mg by intravenous
infusion over 30 min twice on day 1.
• Maintenance dose: 100 mg by intravenous infusion over 30 min once daily or 300 mg orally
once daily.
• Duration: 7 to 14 days.
In 2018, omadacycline was approved by the EMA and FDA for community-acquired bacterial
pneumonia, acute bacterial skin, and skin structure infections [52,54].
Lefamulin is a novel semisynthetic pleuromutilin that inhibits bacterial protein synthesis.
It binds to the peptidyl transferase center of the 50s bacterial ribosome, preventing the binding of
transfer RNA for peptide transfer. Lefamulin expresses antimicrobial activity against gram-positive
(S. pneumoniae, H. influenza) and intracellular pathogens (Mycoplasma pneumoniae, Legionella pneumophila,
and Chlamydophila pneumoniae) associated with CAP but also has activity against MRSA and
vancomycin-resistant Enterococci.
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In a phase III clinical trial (LEAP 1) [55], the efficacy and safety of lefamulin (intravenous and oral)
were compared with those of moxifloxacin (with or without linezolid). The study included 551 adult
patients with bacterial CAP, of whom 276 patients were randomized to receive lefamulin 150 mg
every 12 h and 275 were randomized to receive moxifloxacin 400 mg every 24 h (with or without
linezolid depending on the clinical suspicion of infection by MRSA). Lefamulin was noninferior to
moxifloxacin for the primary the Food and Drug Administration (FDA) efficacy outcome of early
clinical response (87.3% for lefamulin vs. 90.2% for moxifloxacin +/− linezolid; a 2.9% difference,
95%CI −8.5 to 2.8). The new antibiotic also met the European Medicines Agency non-inferiority
endpoint of investigator assessment of clinical response (IACR) at a test-of-cure visit 5–10 days after
therapy (86.9% for lefamulin vs. 89.4% for moxifloxacin +/−linezolid; 2.5% difference, 95% CI −8.4
to 3.4).
In a second phase III clinical trial (LEAP 2) [56], the efficacy and safety of lefamulin (5 days oral)
were compared with those for moxifloxacin (7 days oral) among 738 adults with moderately severe
bacterial CAP. Lefamulin met the FDA primary endpoint of non-inferiority (10.0% margin) for an
early clinical response at 72–120 h following therapy in the intention-to-treat population. Early clinical
response was 90.8% after 5 days of treatment with lefamulin and 90.8% after 7 days of treatment with
moxifloxacin (treatment difference, 0.1; 95% CI −4.4 to 4.5). Lefamulin also met the EMA primary
endpoint of non-inferiority (10.0% margin) based on an IACR of 5–10 days following drug dosing in
the modified intention-to-treat and clinically evaluable at test-of-cure populations. The IACR rates
for the modified intention-to-treat population were 87.5% for lefamulin and 89.1% for moxifloxacin
(treatment difference −1.6; 95% CI −6.3 to 3.1]), whereas for the clinically evaluable at test-of-cure
population, they were 89.7% for lefamulin and 93.6% for moxifloxacin (treatment difference −3.9;
95% CI −8.2 to 0.5]). Lefamulin is currently undergoing FDA and EMA review for the treatment of
CAP, both in intravenous and oral formulations.
7. Conclusions
It is crucial that we identify patients with severe CAP at risk of being infected with PES pathogens.
Specific risk factors, the local ecology, and resistance patterns should always be considered when
determining the most appropriate empirical antibiotic therapy. Our recommendation is to follow
the current international guidelines for empiric therapy in severe CAP and to use the PES score to
categorize patients at risk of infection with PES pathogens, reserving the coverage for PES pathogens
for patients at high risk (i.e., PES score ≥5 points). Of course, clinicians will need to become aware of
the pharmacological characteristics and microbial activities of the new antibiotics approved for the
management of CAP, especially their broad spectrum of coverage.
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